Annals of Medicine · 2023 · 13 citations · 25 references
MedicineMolecular GeneticsOncologyCancer GeneticsGenomicsMolecular OncologyCancer GenomicsCopy Number Variant AnalysisCopy Number VariantsNext-generation SequencingNext-generation Sequencing In OncologyVariant DetectionBiomarkersCancer Gene Panel SequencingCancer Gene Panel TestingClinical Next-generation SequencingLassoLasso RegressionNext-generation Sequencing PanelsTherapeutic Resistance Mechanisms
BACKGROUND: The rapid adoption of next-generation sequencing in clinical oncology has enabled detection of molecular biomarkers which are shared between multiple tumour types. Intra-tumour heterogeneity is a mechanism of therapeutic resistance and therefore an important clinical challenge. However, the tumour-related copy number variants (CNVs), as key regulators of cancer origination, development, and progression, across various types of cancers are poorly understood. METHODS: We performed pan-cancer CNV analysis of cancer-related genes in 15 types of cancers including 1438 cancerous patients by next-generation sequencing using a commercially available pan-cancer panel (Onco PanScan™). Downstream bioinformatics analysis was performed in order to detect CNVs, cluster analysis of the found CNVs, and comparison of the frequency of gained CNVs between different types of cancers. LASSO analysis was used for identification of the most important CNVs. RESULTS: = .001). Common CNVs, such as FOXA1, NFKBIA, HEY1, MECOM, CHD7, AGO2, were mutated in 6.79%, 8.45%, 7.51%, 6.43%, 7.59%, 8.16% of tumours, while most of these mutations have proven roles in positive regulation of transcription from RNA polymerase II promoter. 11 features including sex, DIS3, EPHB1, ERBB2, FLT1, HCK, KEAP1, MYD88, PARP3, TBX3, and TOP2A were found as the key features for classification of cancers using CNVs. CONCLUSION: The 16 common CNVs between cancers can be used to identify the target of pan-cancer drug design and targeted therapies. Additionally, 22 caner-specific CNVs can be used as unique diagnostic markers for each cancer type.
25
TBtools: An Integrative Toolkit Developed for Interactive Analyses of Big Biological Data
Chengjie Chen, Hao Chen, Yi Zhang et al. · Molecular Plant · 2020 · 15.2K citations · Full text
Kai Wang, Siu Tsan Yuen, Jiangchun Xu et al. · Nature Genetics · 2014 · 1.1K citations
Pan-cancer landscape of homologous recombination deficiency
Luan Nguyen, John W.M. Martens, Arne van Hoeck et al. · Nature Communications · 2020 · 536 citations · Full text
Life Sciences, Genetics, Oncology +16
Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors
Sadegh Saghafinia, Marco Mina, Nicolò Riggi et al. · Cell Reports · 2018 · 389 citations · Full text